TY  - CONF

T1  - Long-term efficacy and safety data for dupilumab in a phase 3, open-label extension trial (LIBERTY AD PED-OLE) in patients aged >= 6 to < 12 years with uncontrolled, moderate-to-severe atopic dermatitis (AD)

JO  - JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

PY  - 2021/01/01

AU  - Cork MJ

AU  - Thaci D

AU  - Eichenfield L

AU  - Arkwright PD

AU  - Chen Z

AU  - Delevry D

AU  - O'Malley JT

AU  - Bansal A

ED  - 

VL  - 85

IS  - 3

SP  - AB120

EP  - AB120

Y2  - 2024/12/22

ER  -